Brown Miller Wealth Management LLC Has $1.91 Million Position in Amgen Inc. (NASDAQ:AMGN)

Brown Miller Wealth Management LLC increased its position in Amgen Inc. (NASDAQ:AMGN) by 1.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,632 shares of the medical research company’s stock after buying an additional 100 shares during the quarter. Brown Miller Wealth Management LLC’s holdings in Amgen were worth $1,910,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also added to or reduced their stakes in AMGN. Moneta Group Investment Advisors LLC lifted its position in shares of Amgen by 83,875.6% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock worth $1,980,571,000 after purchasing an additional 7,532,031 shares during the period. Norges Bank bought a new stake in Amgen during the fourth quarter valued at $1,351,778,000. Price T Rowe Associates Inc. MD grew its holdings in Amgen by 158.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,950,013 shares of the medical research company’s stock worth $774,791,000 after acquiring an additional 1,806,456 shares during the period. Morgan Stanley increased its holdings in Amgen by 12.9% in the fourth quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock worth $3,493,471,000 after purchasing an additional 1,523,665 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Amgen by 164.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,337,970 shares of the medical research company’s stock worth $323,548,000 after buying an additional 832,885 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Down 0.7 %

Shares of AMGN stock traded down $1.98 during trading hours on Thursday, hitting $284.32. 2,288,855 shares of the company’s stock traded hands, compared to its average volume of 3,040,904. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. The stock has a market cap of $152.37 billion, a price-to-earnings ratio of 22.81, a PEG ratio of 2.66 and a beta of 0.58. The stock’s fifty day simple moving average is $290.09 and its two-hundred day simple moving average is $280.70. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, beating the consensus estimate of $4.66 by $0.05. The firm had revenue of $8.20 billion for the quarter, compared to analysts’ expectations of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The company’s revenue was up 19.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $4.09 EPS. On average, analysts expect that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 3.17%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 72.06%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Oppenheimer reaffirmed an “outperform” rating and issued a $350.00 target price on shares of Amgen in a research report on Thursday, February 1st. BMO Capital Markets raised shares of Amgen from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $286.00 to $326.00 in a research note on Tuesday, December 19th. StockNews.com downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Tuesday, March 19th. Truist Financial reaffirmed a “buy” rating and issued a $320.00 price target on shares of Amgen in a research report on Wednesday, November 29th. Finally, UBS Group decreased their price objective on Amgen from $315.00 to $314.00 and set a “neutral” rating for the company in a report on Monday, January 29th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $295.30.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.